Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis
Status:
Completed
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
Primary objective:
To evaluate the efficacy of tralokinumab in combination with topical corticosteroids (TCS)
compared with placebo in combination with TCS in treating moderate-to-severe atopic
dermatitis (AD).
Secondary objectives:
To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of
AD, itch, health-related quality of life, and health care resource utilisation compared with
placebo in combination with TCS.
To assess the safety of tralokinumab in combination with TCS when used to treat
moderate-to-severe AD for 16 weeks.